Nanobiotix S.A. ADR (NBTX)

$3.15 -0.15 (-4.55%)
Market Cap 155.54M
Revenue (ttm) -7.78M
Net Income (ttm) -73.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 947.69%
Debt to Equity Ratio 0.00
Volume 5,200
Avg Vol 11,456
Day's Range N/A - N/A
Shares Out 47.13M
Stochastic %K 7%
Beta 0.26
Analysts Strong Sell
Price Target $7.20

Latest News on NBTX

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

Apr 3, 2025, 4:24 PM EDT - 23 days ago

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Apr 2, 2025, 4:15 PM EDT - 24 days ago

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Mar 31, 2025, 2:00 AM EDT - 26 days ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

Mar 27, 2025, 4:15 PM EDT - 4 weeks ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Mar 20, 2025, 4:15 PM EDT - 5 weeks ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Mar 17, 2025, 4:15 PM EDT - 5 weeks ago

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

Jan 29, 2025, 4:15 PM EST - 3 months ago

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Jan 21, 2025, 2:30 AM EST - 3 months ago

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

Dec 17, 2024, 4:15 PM EST - 4 months ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

Dec 9, 2024, 4:15 PM EST - 4 months ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Nov 12, 2024, 2:30 AM EST - 5 months ago

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

NANOBIOTIX to Participate in Multiple Investor Conferences in November

Oct 31, 2024, 3:30 AM EDT - 6 months ago

NANOBIOTIX to Participate in Multiple Investor Conferences in November

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Sep 18, 2024, 4:15 PM EDT - 7 months ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Sep 4, 2024, 4:15 PM EDT - 8 months ago

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:15 PM EDT - 8 months ago

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Jun 12, 2024, 4:15 PM EDT - 11 months ago

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

Jun 2, 2024, 10:00 AM EDT - 11 months ago

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

May 28, 2024, 4:15 PM EDT - 11 months ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript

May 22, 2024, 8:32 PM EDT - 1 year ago

Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

May 22, 2024, 2:00 AM EDT - 1 year ago

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

May 21, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

May 15, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

May 14, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript

Apr 27, 2024, 11:51 AM EDT - 1 year ago

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Apr 24, 2024, 4:40 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Apr 17, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Apr 2, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Nanobiotix to Present at Upcoming Investor Conferences in March

Mar 6, 2024, 4:15 PM EST - 1 year ago

Nanobiotix to Present at Upcoming Investor Conferences in March

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Jan 31, 2024, 4:15 PM EST - 1 year ago

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

Jan 29, 2024, 4:15 PM EST - 1 year ago

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 1:01 PM EST - 1 year ago

Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Nov 13, 2023, 4:15 PM EST - 1 year ago

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

Nov 9, 2023, 4:15 PM EST - 1 year ago

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

NANOBIOTIX Announces Closing of Global Offering

Nov 7, 2023, 4:01 PM EST - 1 year ago

NANOBIOTIX Announces Closing of Global Offering

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

Nov 6, 2023, 2:00 AM EST - 1 year ago

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

Nov 2, 2023, 10:49 AM EDT - 1 year ago

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Nov 1, 2023, 6:32 PM EDT - 1 year ago

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Oct 23, 2023, 2:00 AM EDT - 1 year ago

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Month

Oct 4, 2023, 4:30 PM EDT - 1 year ago

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Month

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

Sep 29, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Sep 28, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Nanobiotix S.A. (NBTX) Q2 2023 Earnings Call Transcript

Sep 27, 2023, 10:52 AM EDT - 1 year ago

Nanobiotix S.A. (NBTX) Q2 2023 Earnings Call Transcript

NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

Sep 26, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

Sep 19, 2023, 4:15 PM EDT - 1 year ago

Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

Sep 5, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Nanobiotix: At A Crucial Juncture For Data

Aug 24, 2023, 8:40 AM EDT - 1 year ago

Nanobiotix: At A Crucial Juncture For Data

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Aug 15, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

Aug 4, 2023, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023